Cytokinetics CEO Robert Blum Executes Stock Sale Under Pre-Arranged Plan
Robert I. Blum, President and Chief Executive Officer of Cytokinetics Inc. (NASDAQ:CYTK), executed a sale of 7,500 shares of the company’s common stock on July 1, 2026. The transaction, valued at approximately $636,900 at a price of $84.92 per share, was conducted under a Rule 10b5-1 trading plan. Following this sale, Mr. Blum retains direct owners…